Skip to main content
NewslettersWatchlist

Merck & Company(MRK-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low101.00
Day High103.23
Open:101.48
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
3 Stocks Poised for a Breakout
MarketBeat
MarketBeat Week in Review – 11/4 - 11/8
PR Newswire
Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
Motley Fool
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Motley Fool
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Motley Fool
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
MarketBeat
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
Barchart
Is This High-Yield Dividend Stock a Buy After Earnings?
MarketBeat
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Motley Fool
Is Pfizer Stock a Bargain for Long-Term Investors?
Motley Fool
Is It Time to Buy October's Worst-Performing Dow Jones Stocks?
Motley Fool
3 Magnificent Stocks Under $100 to Buy in November
Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Motley Fool
Is Merck Stock a Buy?
Motley Fool
Merck (MRK) Q3 2024 Earnings Call Transcript
Motley Fool
3 Dividend Stocks That Could Raise Their Payouts in November
Barchart
Stocks Plunge Before the Open as Microsoft and Meta Weigh on Sentiment, U.S. Inflation Data and Earnings in Focus
Barchart
Stocks Set to Open Higher as Investors Await Key U.S. Economic Data and Big Tech Earnings
Motley Fool
Where Will Merck Be in 5 Years?
Barchart
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?
Motley Fool
3 Absurdly Cheap Stocks That Pay High Dividends
Motley Fool
Up 700% This Year, Is It Too Late to Invest in This Stock?

Profile

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.